Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.
Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K. Sylvester RJ, et al. Among authors: bouffioux c. Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7. doi: 10.1016/j.eururo.2005.12.031. Epub 2006 Jan 17. Eur Urol. 2006. PMID: 16442208
Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies.
Brausi M, Collette L, Kurth K, van der Meijden AP, Oosterlinck W, Witjes JA, Newling D, Bouffioux C, Sylvester RJ; EORTC Genito-Urinary Tract Cancer Collaborative Group. Brausi M, et al. Among authors: bouffioux c. Eur Urol. 2002 May;41(5):523-31. doi: 10.1016/s0302-2838(02)00068-4. Eur Urol. 2002. PMID: 12074794
Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group.
Bouffioux C, Kurth KH, Bono A, Oosterlinck W, Kruger CB, De Pauw M, Sylvester R. Bouffioux C, et al. J Urol. 1995 Mar;153(3 Pt 2):934-41. J Urol. 1995. PMID: 7853578 Clinical Trial.
A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer.
Pawinski A, Sylvester R, Kurth KH, Bouffioux C, van der Meijden A, Parmar MK, Bijnens L. Pawinski A, et al. Among authors: bouffioux c. J Urol. 1996 Dec;156(6):1934-40, discussion 1940-1. J Urol. 1996. PMID: 8911360
Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of a European organization for research on treatment of cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin. The European Organization for Research on Treatment of Cancer Genitourinary Group.
Bouffioux C, Denis L, Oosterlinck W, Viggiano G, Vergison B, Keuppens F, De Pauw M, Sylvester R, Cheuvart B. Bouffioux C, et al. J Urol. 1992 Aug;148(2 Pt 1):297-301. doi: 10.1016/s0022-5347(17)36577-1. J Urol. 1992. PMID: 1635122 Clinical Trial.
Phase II trials in Ta, T1 bladder cancer. The marker tumour concept.
van der Meijden AP, Hall RR, Kurth KH, Bouffioux C, Sylvester R. van der Meijden AP, et al. Among authors: bouffioux c. Br J Urol. 1996 May;77(5):634-7. doi: 10.1046/j.1464-410x.1996.09002.x. Br J Urol. 1996. PMID: 8689102 Review. No abstract available.
105 results